DR [Dermatology Reports 2015; 7:6246] [page 39] Exploring valrubicin’s effect on Propionibacterium acnes-induced skin inflammation in vitro and in vivo Louise Rottboell,1 Sarah de Foenss,1 Kenneth Thomsen,2 Helle Christiansen,1 Stine M. Andersen,1 Tomas N. Dam,3 Cecilia Rosada,1 Karin Stenderup1 1Department of Dermatology, Aarhus University Hospital; 2Department of Biomedicine, Aarhus University; 3Department of Dermatology, Roskilde Hospital, Denmark Abstract Acne is a common skin disease involving colonization with Propionibacterium acnes (P. acnes), hyperproliferation of the follicular epithelium and inflammatory events. Valrubicin is a second-generation anthracy- cline, non-toxic upon contact, and available in a topical formulation. Valrubicin’s predecessor doxorubicin possesses antibacterial effects and previously we demonstrated that valru- bicin inhibits keratinocyte proliferation and skin inflammation suggesting beneficial topi- cal treatment of acne with valrubicin. This study aims to investigate valrubicin’s possible use in acne treatment by testing valrubicin’s antibacterial effects against P. acnes and P. acnes-induced skin inflammation in vitro and in vivo. Valrubicin was demonstrated not to possess antibacterial effects against P. acnes. Additionally, valrubicin was demonstrated not to reduce mRNA and protein expression levels of the inflammatory markers interleukin (IL)- 1β, IL-8, and tumor necrosis factor (TNF)-α in vitro in human keratinocytes co-cultured with P. acnes. Moreover, in vivo, valrubicin, applied both topically and intra-dermally, was not able to reduce signs of inflammation in mouse ears intra-dermally injected with P. acnes. Taken together, this study does not support beneficial antibacterial and anti inflammatory effects of topical valrubicin treatment of acne. Introduction Acne vulgaris is one of the most common skin diseases worldwide affecting more than 85% of all adolescents.1 The disease presents a significant clinical problem with severe social and psychological implications. The pathogen- esis of acne is multifactorial and usually impli- cates follicular colonization with the gram-pos- itive anaerobe Propionibacterium acnes (P. acnes) and inflammation upon manifesta- tion.2,3 P. acnes has previously been shown to stimulate secretion of pro-inflammatory cytokines such as interleukin (IL)-1β, IL-8 and tumor necrosis factor (TNF)-α.4 Current acne treatments present side effects such as skin irritation, bacterial resistance, teratogen effects, and chronicity rendering acne as a dis- ease with persistent need for new and improved treatment modalities.1 Valrubicin (N-trifluoroacetyladriamycin-14- valerate) is a second-generation anthracycline currently FDA-approved for intra-vesical treat- ment of bacillus Calmette-Guérin-refractory bladder cancer.5 Valrubicin is derived from doxorubicin, which exhibits both antibiotic and antineoplastic activities.5,6 Valrubicin excels by lacking contact and cardiac toxicity.6 Valrubicin’s improved safety profile and excel- lent tissue penetration5,6 has led to the devel- opment of a cream formulation facilitating top- ical application and possible treatment of hyperproliferative skin diseases as demon- strated by alleviation of psoriasis and preven- tion of skin tumor development in mouse mod- els;7,8 an effect ascribed to valrubicin’s ability to inhibit keratinocyte proliferation and skin inflammation.7-9 In this study, we aim to investigate whether topical valrubicin treatment may play a future role in acne treatment, thus valrubicin’s antibac- terial effect against P. acnes is tested together with valrubicin’s anti-inflammatory effect on P. acnes-induced inflammation in vitro and in vivo. Valrubicin did not demonstrate antibacterial effects nor did it reduce expression levels of IL- 1β, IL-8, and TNF-α, in vitro, or reduce signs of inflammation in vivo. In conclusion, this study does not support beneficial antibacterial and anti-inflammatory effects of topical valrubicin treatment of P. acnes-associated acne. The sub- mitted manuscript includes primary normal human epidermal keratinocytes (NHEKs), iso- lated from healthy donors undergoing skin reductive surgery. All donors have signed a donor consent letter and the project is approved by the regional ethical committee (Den vidensk- absetiske Komité for Århus Amt) with journal number 20030125. The submitted manuscript also includes animal experimentation which is approved by the Danish Animal Experiments Inspectorate (Dyreforsøgstil synet) with journal number 2011/561-1958. Materials and Methods P. acnes bacteria Three different P. acnes strains: 1.4.L1, 12.1.L1 and 30.2.L1, were included in this study. 1.4.L1 and 12.1.L1 are sequence type (ST)18 and strongly associated with moderate to severe acne while 30.2.L1 is ST27 and asso- ciated with healthy skin. Strains were kindly provided by Professor Mogens Kilian, Institute of Biomedicine, Aarhus University, Denmark, and isolated from acne patients as previously described.10-12 P. acnes were inoculated on 5% blood agar or reinforced clostridium agar and incubated under anaerobic conditions at 37°C. Further growth was accomplished by inocula- tion on dialysis membranes (3500 Dalton, 3 Spectra/Por® no.: 132725, Spectrum Laboratories, Breda, the Netherlands) on 5% blood agar for four days or by re-suspension in brain heart infusion broth until reaching log phase growth. Bacteria were harvested, washed and re-suspended in isotonic saline water and used immediately. Dermatology Reports 2015; volume 7:6246 Correspondence: Karin Stenderup, Research Centre S., Department of Dermatology, Aarhus University Hospital, P.P. Oerumsgade 11, bldg. 15b, DK-8000 Aarhus C, Denmark. Phone: +45.7846.1838 - Fax: +45.7846.1850. E-mail: karin.stenderup@clin.au.dk Key words: Propionibacterium acnes; valrubicin; acne; skin inflammation; mouse model. Acknowledgements: the authors thank Annette Blak Rasmussen, Winnie Heidemann and Tove Findahl for their excellent technical assistance, Lars Iversen and Mogens Kilian for making avail- able laboratory facilities, and Mogens Kilian and Holger Brüggemann for guidance. We thank Elisabeth de Darkó from Valderm ApS for supply- ing valrubicin. Contributions: LR, TND, CR, KS, conception of the work; LR, SdF, KT, HC, SMA, acquisition of data for the work; LR, TND, CR, KS, analysis and interpretation of data for the work; LR, SdF, KT, HC, SMA, TND, CR, KS, drafting the work and critically revising it for important intellectual content and final approval of the manuscript ver- sion to be published. Conflict of interest: LR, SdF, KT, HC, SMA, CR, declare no conflict of interest; KS received fund- ing for operating expenses from Valderm ApS; TND is a consultant at Valderm ApS. Funding: this work was financially supported by Valderm ApS; Institute of Clinical Medicine, Aarhus University; Aage Bang’s Foundation. Received for publication: 19 October 2015. Accepted for publication: 29 November 2015. This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY- NC 3.0). ©Copyright L. Rottboell et al., 2015 Licensee PAGEPress, Italy Dermatology Reports 2015; 7:6246 doi:10.4081/dr.2015.6246 No n c om me rci al us e o nly [page 40] [Dermatology Reports 2015; 7:6246] Antibacterial assay TYEG agar supplemented with 2 μg/mL of furazolidone to inhibit growth of staphylo - cocci,13 was used to test the antibacterial activ- ity of valrubicin against P. acnes. Valrubicin in different concentrations and formulations were loaded onto sterile filter discs and placed on the surface of inoculated agar plates. Valrubicin 250 mg/mL in acetone (kindly pro- vided by Valderm ApS, Lyngby, Denmark), 25 mg/mL in acetone/DMSO [1:10], 5 μg/mL in acetone/sterile water [1:10,000], 40 mg/mL (Valstar®) in cremophor/ethanol [1:1], (kind- ly provided by Valderm ApS), 10 mg/mL (Valstar®) in cremophor/ethanol/sterile water [1:1:4], 10 mg/mL in cream (1% batch 7077/001, kindly provided by Valderm ApS), 10 mg/mL in cream gel (1% batch 7078/001, kindly provided by Valderm ApS) and the vehicles: acetone, acetone/DMSO [1:10], acetone/ster- ile water [1:10,000], Cremophor® L (C5135, Sigma-Aldrich, Broendby, Denmark)/ethanol [1:1], Cremophor® L (C5135, Sigma- Aldrich)/ethanol/sterile water [1:1:4], cream and gel vehicles (kindly provided by Valderm ApS) were tested. Discs with penicillin (5 μg, Roscolab Ltd., London, UK) were added as pos- itive control. Plates were incubated under anaerobic conditions at 37°C for three days. Antibacterial potential was determined as growth inhibition of the bacterial layer. Keratinocyte cell cultures Primary normal human epidermal ker- atinocytes (NHEKs) were isolated from four healthy donors undergoing skin reductive sur- gery. Informed consent was obtained and the study was approved by the Central Ethical Committee and conducted in accordance with the Declaration of Helsinki protocols. NHEKs were grown in keratinocyte serum-free medi- um (K-SFM, Invitrogen) containing the sup- plements for keratinocyte growth (epidermal growth factor and pituitary extract; Invitrogen), at standard conditions (37°C, 5% CO2, and 90% humidity) as previously described.14 24 hrs prior to co-culturing NHEKs with P. acnes, medium was removed, cells washed in PBS (Invitrogen), and new medium without antibiotics added. P. acnes were re- suspended in Dulbecco’s Modified Eagle’s Medium (DMEM, Invitrogen, Carlsbad, CA, USA) containing 10% FBS without antibiotics prior to co-culture. The P. acnes strain 1.4.L1, associated with acne, was used. In house, unpublished results, demonstrated that freshly prepared P. acnes, harvested in log phase growth, stimulated a greater inflammatory response compared with thawed P. acnes, thus freshly prepared P. acnes were used throughout the study. The effect of valrubicin on P. acnes-induced expression levels of inflammatory cytokines in NHEKs was determined by assessing five dif- ferent treatment groups. Group 1 was not co- cultured with P. acnes, and served as negative control. Groups 2, 3, and 4 were co-cultured with P. acnes (strain 1.4.L1, 103 freshly pre- pared P. acnes/NHEK). 30 minutes post P. acnes challenge, group 3 and 4 were furthermore treated with valrubicin (5.0 μg/mL, diluted 1:5,000 in acetone) or vehicle (acetone diluted 1:5,000). Group 5 was treated with valrubicin (5.0 μg/mL diluted 1:5,000 in acetone) alone. Each treatment group was performed in tripli- cate from each of the four donors. Measurement of inflammatory cytokine mRNA and protein expression levels To analyze mRNA expression levels, cells were harvested 2.5 hrs post P. acnes co-culture (2 hrs post valrubicin or vehicle treatment) by transferring cells to ice, washing in ice-cold PBS (Invitrogen) and adding RNA-lysis-buffer including β-mercaptoethanol (SV 96 Total RNA Isolation System, Promega, Madison, WI, USA). Lysed cell samples were stored at −80°C until processed for RNA purification. RNA was isolated according to the SV Total RNA Isolation System vacuum protocol (Promega) and cDNA and quantitative real-time reverse transcription-polymerase chain reaction (PCR) was performed as previously described.9 Expression of IL-1β, IL-8 and TNF-α was deter- mined by TaqMan® Gene Expression Assays (Assay ID: IL-1β: Hs00174097_m1, IL-8: Hs00174103_m1, TNF-α: Hs01113624_g1, Applied Biosystems, San Francisco, CA, USA). RPLP0 was used as internal reference (Assay ID: RPLP0: Hs99999902_m1, Applied Biosystems). The expression of each gene was analyzed in triplicate. To analyze expression levels of secreted proteins, cell supernatants were removed 12.5 hrs post P. acnes stimula- tion (12 hrs post valrubicin or vehicle treat- ment), snap-frozen in liquid nitrogen and stored at −80°C until processed in the enzyme- linked immunosorbent assay (ELISA) as previ- ously described by use of DuoSet® ELISA development kits (IL-1β/IL-1F2: DY201, CXCL8/IL-8: DY208, and TNF-α: DY210; R&D Systems, Abingdon, UK).9 The expression of each protein was analyzed in triplicate. P. acnes-induced ear inflammation mouse model C57BL/6J female mice (6-10 weeks old) (Taconic, Ry, Denmark) were housed under standard conditions with a 12 hrs light/dark cycle and controlled temperature. Animals were fed a standard rodent laboratory diet and given water ad libitum. During intra-dermal injection of P. acnes, measurement of ear thickness, and topical and intra-dermal injec- tion treatment with valrubicin or vehicle, mice were anaesthetized in isoflurane (2-3.75%). At the end of the experiment, mice were sacri- ficed by cervical dislocation. Animal experi- ments were approved by The Danish Experimental Animal Inspectorate. Ear inflam- mation was induced in mouse ears by chal- lenging ears with intra-dermal injections of 10 µL (6×107) or 15 µL (9×107) freshly prepared P. acnes (strain 1.4.L1) re-suspended in isotonic saline water. No ear inflammation was observed in control mice intradermally inject- ed with only isotonic saline water after 24 hrs (data not shown). To test the effect of valru- bicin as topical treatment a short term (1 day) and a long term (2 weeks) experiment was per- formed. Valrubicin (10 μg/μL dissolved in ace- tone) and vehicle (acetone) was administered in a volume of 10 μL per dorsal and 10 μL per ventral surface of each ear. In the short term experiment mouse ears were treated once top- ically, 30 minutes post challenge, with valru- bicin (group 1, n=9) or vehicle (acetone, group 2, n=16) and ear thickness was measured before (0 hrs) and 24 hrs after challenge. In the long-term experiment, mouse ears were divided into five groups where groups 1 and 2, and groups 3 and 4 were challenged with 6×107 or 9×107 freshly prepared P. acnes, respectively. 30 minutes post challenge and daily hereafter throughout the study, ears were treated topi- cally with valrubicin (group 1, n=7 and group 3, n=8) or vehicle (acetone, group 2, n=4 and group 4, n=8). As control, an additional group of mouse ears (group 5, n=8) was left unchal- lenged but treated daily with valrubicin throughout the study. To test the effect of intra-dermal valrubicin treatment, 2 weeks post challenge, mouse ears were treated daily for 3 days with intra-dermal injections of valru- bicin (Valstar®, 10 μL, group 1, n=12) or vehi- cle (cremophor/ethanol [1:1], 10 μL, group 2, n=11). As control, an additional group of chal- lenged mouse ears were left untreated (group 3, n=9). Ear thickness was measured by a Mitutoyo digimatic indicator (Mitutoyo, Kawasaki, Japan) prior to and at indicated time points after ear challenge. Statistics For statistical analysis the two-tailed Student’s t-test was employed. P<0.05 was con- sidered significant. Results Valrubicin’s antibacterial effect against P. acnes Valrubicin’s antibacterial effect against P. acnes was tested by employing different con- centrations and formulations of valrubicin Article No n c om me rci al us e o nly [Dermatology Reports 2015; 7:6246] [page 41] (Table 1). Three P. acnes strains: clinical iso- lates 1.4.L1, 12.1.L1, and 30.2.L1 were inoculat- ed on agar plates but no signs of bacterial clearing were demonstrated. Valrubicin’s effect on P. acnes-induced inflammation in keratinocytes in vitro Valrubicin’s effect on P. acnes-induced inflammation in keratinocytes in vitro was tested in NHEKs co-cultured with freshly pre- pared P. acnes. P. acnes only significantly induced an increase in the mRNA expression level of IL-1β (Figure 1a) but not IL-8 (Figure 1b) and TNF-α (Figure 1c). The observed increased mRNA expression level of IL-1β and the existing expression levels of IL-8 and TNF- α were not affected by valrubicin treatment (P=0.98 for IL-1β, ��P=0.52 for IL-8, and P=0.88 for TNF-α). P. acnes significantly increased protein expression levels of both IL-1β (Figure 1d), IL-8 (Figure 1e) and TNF-α (Figure 1f), however, valrubicin treatment was demon- strated not to reduce the P. acnes-induced expression levels of IL-1β (P=0.54), IL-8 (P=0.94), and TNF-α (P=0.76). Valrubicin’s effect on P. acnes- induced skin inflammation in vivo Valrubicin’s effect on P. acnes-induced skin inflammation in vivo was tested by treating mouse ears, challenged by injection of P. acnes. Short term (1 day) topical valrubicin treatment demonstrated no reduction in ear thickness (Figure 2a); ear thickness in both valrubicin and vehicle treated mouse ears was increased approximately 2-fold after 24 hrs. Long term (2 weeks) daily topical valrubicin treatment was tested in repeated experiments where mouse ears were injected with the same amount of P. acnes (Figure 2b) or 30% fewer P. acnes (Figure 2c). No reduction in ear thickness was seen in valrubicin treated mouse ears com- pared with vehicle treated ears, at any time point during the 2 weeks. Ear thickness, in both the valrubicin and vehicle treated mouse ears, increased approximately 3-fold (Figure 2b) and 2-fold (Figure 2c) after 24 hrs. Mouse ears treated with valrubicin alone, demonstrat- ed no change in ear thickness during the 2 weeks. Repeated acetone-applications have previously been demonstrated, by our group, not to affect ear thickness.9 In a final experi- ment, to facilitate the ability of valrubicin to locate directly into the site of inflammation, valrubicin was injected intra-dermally into the mouse ears (Figure 2d). No effect of valrubicin as compared with vehicle, on ear thickness, was observed. Article Figure 1. Valrubicin’s effect on P. acnes-induced mRNA and protein expression levels of inflammatory cytokines by NHEKs. NHEKs from four healthy donors, were cultured in the presence of freshly prepared P. acnes. The effect of valrubicin on P. acnes-induced mRNA expression levels of IL-1β (a), IL-8 (b), and TNF-α (c) was evaluated after 2 hrs of stimulation. mRNA expression levels were normal- ized to the expression levels of the housekeeping gene, ribosomal protein large P0 (RPLP0) and to the untreated control (no P. acnes bacteria added). The effect of valrubicin on P. acnes-induced protein expression levels of IL-1β (d), IL-8 (e), and TNF-α (f) was eval- uated after 12 hrs of stimulation. Protein expression levels were determined by ELISA and normalized to the untreated control (no P. acnes bacteria added). Values are presented as mean + standard deviation (NHEKs, n=4 donors, cultured in triplicate). Table 1. Valrubicin’s antibacterial effect on P. acnes. Valrubicin concentration and formulation 1.4.L1 12.1.L1 30.2.L1 250 mg/mL in acetone * * * 25 mg/mL in acetone/DMSO (1:10) * * * 5 μg/mL in acetone/sterile water (1:10,000) * * * 40 mg/mL (Valstar®) in cremophor/ethanol (1:1) * * * 10 mg/mL (Valstar®) in cremophor/ethanol/sterile water (1:1:4) * * * 10 mg/mL in cream (1% batch) * * * 10 mg/mL in cream gel (1% batch) * * * * indicates no clearing of the bacterial layer. Vehicles alone demonstrated no antibacterial effect and penicillin, used as positive control, showed strong bacterial clearing in all three P. acnes strains. No n c om me rci al us e o nly [page 42] [Dermatology Reports 2015; 7:6246] Discussion Several treatment modalities exist for acne, however, some may be associated with adverse side effects and therapeutic failure.1 Thus, research is focused on discovering new and improved treatments to expand the current treatment palette. The role of P. acnes in the pathogenesis of acne has been discussed, as P. acnes is also a commensal of healthy skin.2 Recent findings, by multi-locus sequence typing (MLST), how- ever, have shown that P. acnes can be divided into different strains associated with either moderate to severe acne, healthy skin or opportunistic infections.10,12 Nevertheless, the majority of acne treatments, currently avail- able, are associated with anti-inflammatory effects and not necessarily antibacterial effects. Interestingly, prolonged antibiotic treatment, associated with high degree of P. acnes resistance, often alleviates acne lesions; a fact explained by anti-inflammatory effects of the antibiotics.15,16 Valrubicin did not demonstrate anti-inflam- matory effects on primary keratinocytes co-cul- tured with P. acnes, as measured by mRNA and protein expression levels of IL-1β, IL-8, and TNF-α. These findings were surprising as we previously demonstrated that 2 hrs of valru- bicin treatment significantly reduced mRNA expression levels of IL-1β and IL-6 in 12-O- tetradecanoylphorbol 13-acetate (TPA) treated mouse ears,9 and because 2 hrs of valrubicin treatment demonstrated to significantly reduce mRNA expression levels of IL-1β, IL-8 and TNF-α in stimulated keratinocytes and immune cells (unpublished results). Moreover, we previously demonstrated that 8 hrs and 24 hrs of valrubicin treatment significantly reduced protein expression levels of IL-1β and IL-6 in TPA treated mouse ears.9 Also, we pre- viously reported that the employed concentra- tion of valrubicin (5.0 μg/mL) was able to inhibit proliferation of NHEKs in cell culture.7 Why valrubicin reduces TPA-induced inflam- mation and not P. acnes-induced inflammation is unclear. IL-1β, IL-8 and TNF-α are expressed in human acne lesions,17-20 and P. acnes has previ- ously been demonstrated to stimulate secre- tion of these pro-inflammatory cytokines in keratinocytes.21-25 The fact that IL-1β is up-reg- ulated in acne skin17 has proposed beneficial effects of IL-1β-targeted therapy which was recently shown to be the case, in patients suf- fering from auto-inflammatory syndromes including acne-lesions.26-28 Topical valrubicin treatment did not reduce P. acnes-induced ear inflammation following short and long term treatments. In a similar study, by our group, Hauge et al. induced both acute and chronic inflammation in the same mouse strain by stimulating mouse ears topi- cally with TPA.9 In this study, topical valrubicin treatment significantly reduced TPA-induced ear inflammation in both the acute and the chronic model. In both studies, topical valru- bicin was applied in equal amounts and con- centrations. Again, why valrubicin reduces TPA-induced inflammation and not P. acnes- induced inflammation is unclear. Previous studies have successfully demon- strated anti-inflammatory effects in the employed P. acnes injected ear-inflammation model.17,29 Similar numbers of P. acnes were injected, however different P. acnes strains were employed. These studies demonstrated a similar 2-4 fold increase in ear thickness upon P. acnes injection which then decreased upon Article Figure 2. Effect of valrubicin treatment on P. acnes-induced ear inflammation. Ear inflammation was induced in mouse ears by chal- lenging ears with intra-dermal injection of 15 μL (9×107; a and b) or 10 μL (6×107; c and d) freshly prepared P. acnes (clinical strain 1.4.L1). Short term (1 day) topical valrubicin treatment (a): 30 minutes post challenge, ears were treated topically with valrubicin (group 1, n=9) or vehicle (acetone, group 2, n=16). Long term (2 weeks) topical valrubicin treatment (b, c): 30 minutes post challenge and daily hereafter throughout the study, ears were treated topically with valrubicin group 1 (n=7) and group 3 (n=8) or vehicle (ace- tone) group 2 (n=4) and group 4 (n=8). As control, an additional group of mouse ears (group 5, n=8) was left unchallenged but treated daily with valrubicin throughout the study. Intra-dermal valrubicin treatment (d): 2 weeks post challenge, ears were treated daily for 3 days with central intra-dermal injections of valrubicin (Valstar®) group 1 (n=12) or vehicle (cremophor/ethanol [1:1]) group 2 (n=11). As control, an additional group of challenged ears were left untreated group 3 (n=9). Ear thickness was measured at indicated time points. Values are presented as mean ± standard deviation. No n c om me rci al us e o nly [Dermatology Reports 2015; 7:6246] [page 43] treatment. Decreased levels of IL-1β, IL-8 and TNF-α��in this model, upon treatment, have also been demonstrated.29 Conclusions Taken together, valrubicin did not demon- strate antibacterial effects against P. acnes nor did it reduce P. acnes-induced inflammation in vitro and in vivo. Acne is, however, a multifac- torial disease, and valrubicin may, despite the lack of antibacterial and anti-inflammatory effects, demonstrate beneficial effects on other aspects of the disease. References 1. James WD. Clinical practice. Acne. N Engl J Med 2005;352:1463-72. 2. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a glob- al alliance to improve outcomes in acne. J Am Acad Dermatol 2003;49:S1-37. 3. Ayer J, Burrows N. Acne: more than skin deep. Postgrad Med J 2006;82:500-6. 4. Vowels BR, Yang S, Leyden JJ. Induction of proinflammatory cytokines by a soluble factor of propionibacterium acnes: impli- cations for chronic inflammatory acne. Infect Immun 1995;63:3158-65. 5. Kuznetsov DD, Alsikafi NF, O’Connor RC, et al. Intravesical valrubicin in the treat- ment of carcinoma in situ of the bladder. Expert Opin Pharmacother 2001;2:1009- 13. 6. Krishan A, Dutt K, Israel M, et al. Comparative effects of adriamycin and n- trifluoroacetyladriamycin-14-valerate on cell kinetics, chromosomal damage, and macromolecular synthesis in vitro. Cancer Res 1981;41:2745-50. 7. Rosada C, Stenderup K, de Darkó E, et al. Valrubicin in a topical formulation treats psoriasis in a xenograft transplantation model. J Invest Dermatol 2010;130:455-63. 8. Andersen SM, Rosada C, Dagnaes-Hansen F, et al. Topical application of valrubicin has a beneficial effect on developing skin tumors. Carcinogenesis 2010;31:1483-90. 9. Hauge E, Christiansen H, Rosada C, et al. Topical valrubicin application reduces skin inflammation in murine models. Br J Dermatol 2012;167:288-95. 10. Lomholt HB, Kilian M. Population genetic analysis of propionibacterium acnes iden- tifies a subpopulation and epidemic clones associated with acne. PloS One 2010;5:e12277. 11. Bruggemann H, Lomholt HB, Tettelin H, et al. Crispr/cas loci of type ii propionibac- terium acnes confer immunity against acquisition of mobile elements present in type i p. acnes. PloS One 2012;7:e34171. 12. Kilian M, Scholz CF, Lomholt HB. Multilocus sequence typing and phyloge- netic analysis of propionibacterium acnes. J Clin Microbiol 2012;50:1158-65. 13. Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from europe. Br J Dermatol 2003;148:467-78. 14. Kragballe K, Desjarlais L, Voorhees JJ. Leukotrienes b4, c4 and d4 stimulate DNA synthesis in cultured human epidermal keratinocytes. Br J Dermatol 1985;113:43- 52. 15. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 1978;70:51- 5. 16. Webster GF, Leyden JJ, McGinley KJ, et al. Suppression of polymorphonuclear leuko- cyte chemotactic factor production in pro- pionibacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline, and erythromycin. Antimicrob Agents Chemother 1982;21: 770-2. 17. Kistowska M, Gehrke S, Jankovic D, et al. Il-1beta drives inflammatory responses to propionibacterium acnes in vitro and in vivo. J Invest Dermatol 2014;134:677-85. 18. Ingham E, Eady EA, Goodwin CE, et al. Pro- inflammatory levels of interleukin-1 alpha- like bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol 1992;98:895-901. 19. Kang S, Cho S, Chung JH, et al. Inflammation and extracellular matrix degradation mediated by activated tran- scription factors nuclear factor-kappab and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol 2005;166:1691- 9. 20. Trivedi NR, Gilliland KL, Zhao W, et al. Gene array expression profiling in acne lesions reveals marked upregulation of genes involved in inflammation and matrix remodeling. J Invest Dermatol 2006;126:1071-9. 21. Akaza N, Akamatsu H, Kishi M, et al. Effects of propionibacterium acnes on var- ious mrna expression levels in normal human epidermal keratinocytes in vitro. J Dermatol 2009;36:213-23. 22. Graham GM, Farrar MD, Cruse-Sawyer JE, et al. Proinflammatory cytokine production by human keratinocytes stimulated with propionibacterium acnes and p. Acnes groel. Br J Dermatol 2004;150:421-8. 23. Nagy I, Pivarcsi A, Koreck A, et al. Distinct strains of propionibacterium acnes induce selective human beta-defensin-2 and interleukin-8 expression in human ker- atinocytes through toll-like receptors. J Invest Dermatol 2005;124:931-8. 24. Akaza N, Akamatsu H, Kishi M, et al. Normal human epidermal keratinocytes react differently than hacat keratinocyte cell line on exposure to propionibacterium acnes. J Dermatol 2011;38:499-502. 25. Isard O, Leveque M, Knol AC, et al. Anti- inflammatory properties of a new undecyl- rhamnoside (aprc11) against p. Acnes. Arch Dermatol Res 2011;303:707-13. 26. Brenner M, Ruzicka T, Plewig G, et al. Targeted treatment of pyoderma gan- grenosum in papa (pyogenic arthritis, pyo- derma gangrenosum and acne) syndrome with the recombinant human interleukin- 1 receptor antagonist anakinra. Br J Dermatol 2009;161:1199-201. 27. Braun-Falco M, Kovnerystyy O, Lohse P, et al. Pyoderma gangrenosum, acne, and sup- purative hidradenitis (pash)—a new autoinflammatory syndrome distinct from papa syndrome. J Am Acad Dermatol 2012;66:409-15. 28. Wendling D, Prati C, Aubin F. Anakinra treatment of sapho syndrome: Short-term results of an open study. Annals of the rheumatic diseases 2012;71:1098-100. 29. Lee WR, Kim KH, An HJ, et al. The protec- tive effects of melittin on propionibacteri- um acnes-induced inflammatory respons- es in vitro and in vivo. J Invest Dermatol 2014;134:1922-30. Article No n c om me rci al us e o nly